Inovio Pharmaceuticals Inc. (INO) stock prices were down by 0.89% as of the market closing on September 22nd, 2021. This brought the price per share down to USD$7.79 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 1.16%, bringing it up to USD$7.88.
INO Stock Gains Approval
September 22nd, 2021 announced having received authorization from COFEPRIS to conduct a clinical trial in Mexico. The approval will allow the commencement of the Phase 3 segment of INO stock’s global Phase 2/3 trial, INNOVATE. The trial is for the company’s DNA vaccine candidate for Covid-19, INO-4800. The company is collaborating with its partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. on the INNOVATE Phase 3 segment in multiple countries. The company recently announced having been granted regulatory authorization to commence Phase 3 clinical trial in Brazil and the Philippines. Further authorization to conduct trials in other countries is currently being pursued.
Phase 3 INNOVATE Trial
The global Phase 3 segment of the INNOVATE trial is designed to evaluate the efficacy of INO-4800. The treatment will consist of a two dose regimen, with each dose amounting to 2 mg. the doses will be administered one month apart, in a 2 to 1 randomization in men and non-pregnant women above the age of 17. The primary endpoint of the case-driven Phase 3 trial is virologically confirmed Covid-19.
INO Stock Works with Authorities
INO stock is keen to continue collaborating with health authorities and investigators in Mexico, Brazil, and the Philippines. These partnerships are set to advance the evaluation of INO-4800 as a solution in the ongoing global fight against the coronavirus pandemic. With millions of people around the world still remaining unvaccinated, the company is committed to supporting the international public health response.
Scope of INO-4800
Accordingly, INO stock is well positioned to evaluate the efficacy of INO-4800, which will prove to be a critical developmental milestone. The company is confident that its proprietary Covid-19 vaccine is uniquely suited to contribute to global efforts. This is on the basis of its strong safety and thermostability profile, ability to generate cross-reactive immune responses, and its potential to function in a primary series as well as a booster vaccine.
Future Outlook for INO Stock
With the world hurtling towards universal immunizations, INO stock is poised to capitalize on the burgeoning scope of opportunities. The company is keen to accelerate the development and proliferation of its INO-4800 treatment. Current and potential investors are confident that management will be able to effectively leverage the resources at their disposal. This is hoped to usher in significant and sustained increases in shareholder value.
